Latent Toxoplasmosis and Human

  • A Dalimi Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • A Abdoli Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Keywords: Toxoplasmosis, Toxoplasma gondii, Mental disorder, Behavioral parameter

Abstract

Toxoplasmosis is one of the most common parasitic diseases worldwide. Although estimated that one third of the world's population are infected with Toxoplasma gondii, but the most common form of the disease is latent (asymptomatic). On the other hand, recent findings indicated that la­tent toxoplasmosis is not only unsafe for human, but also may play various roles in the etiol­ogy of different mental disorders. This paper reviews new findings about importance of latent toxop­lasmosis (except in immunocompromised patients) in alterations of behavioral parameters and also its role in the etiology of schizophrenia and depressive disorders, obsessive-compulsive disorder, Alzheimer's diseases and Parkinson's disease, epilepsy, headache and or migraine, men­tal retardation and intelligence quotients, suicide attempt, risk of traffic accidents, sex ratio and some possible mechanisms of T. gondii that could contribute in the etiology of these alterations.

References

Montoya JM, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363: 1965-1976.

Weiss LW, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009; 39: 895–901.

Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002; 8: 634–640.

Bhopale GM. Pathogenesis of toxoplasmosis. Comp Immun Microbiol Infect Dis. 2003; 26: 213–222.

Maubon D, Ajzenberg D, Brenier-Pinchart MP, Darde ML, Pelloux H. What are the respective host and parasite contributions to toxoplasmosis? Trends Parasitol. 2008; 24: 299-303.

Vallochi AL, Muccioli C, Cristina Martins M, Silveira C, Belfort R, Vicente Rizzo L. The Genotype of Toxoplasma gondii Strains Causing Ocular Toxoplasmosis in Humans in Brazil. Am J Ophthalmol. 2005; 139: 350–351.

Ajzenberg D, Cogne N, Paris L, Bessieres MH, Thulliez P, Fillisetti D, Pelloux H, Marty P, Darde´ ML. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis and correlation with clinical findings. J Infect Dis. 2002; 186:684–689.

Khan A, Su C, German M, Storch GA, Clifford DB, Sibley LD. Genotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strains. J Clin Microbiol. 2005; 43(12):5881-7.

Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000; 30: 1217–1258.

Shahmoradi A, Rezaian M, Dalimi A. Sheep an important reservoir of human toxoplasmosis in Iran. Med J IR.Iran. 1993; 7( 3): 173-174.

Sharifian M, Dalimi A, Kazemi B. Early diagnosis of toxoplasmosis by PCR method in the blood of experimentally infected rats. J Vet Res. 2003; 58(4):323-327.

Zare F, Dalimi A, Ghaffarifar F. Detection of active Toxoplasma godii (RH strain) in the different body tissues of experimentally infected rats. Modares J Med Sci. 2006; 9(1):19-23.

Carruthers VB, Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull. 2007; 33: 745–751.

Stahl W, Kaneda Y, Noguchi T. Reproductive failure in mice chronically infected with Toxoplasma gondii. Parasitol Res. 1994; 80:22–28.

Stahl W, Kaneda Y. Impaired thyroid function in murine toxoplasmosis. Parasitology. 1998; 117:217–22.

Abdoli A, Dalimi A, Movahedin M. Impaired reproductive function of male rats infected with Toxoplasma gondii. Anderolgia. 2012; doi: 10.1111/j.1439-0272.2011.01249.x [Epub ahead of print].

Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009; 31:706–15.

Flegr J. Effects of Toxoplasma on Humanm Behavior. Schizophr Bull. 2007; 33: 757–760.

Webster JP. Rats, cats, people and parasites: the impact of latent toxoplasmosis on behavior. Microb Infect. 2001; 3: 1037−1045.

Webster JP. The Effect of Toxoplasma gondii on animal behavior: Playing Cat and Mouse. Schizophr Bull. 2007; 33: 752–756.

Abdoli A, Bahrami F, Dalimi A, Ghaffarifar F. Effect of toxoplasmosis on central nervous system. J Contemporary Neuroscience. 2011; 31-31: 5-15.

Flegr J, Hrdy I. Influence of chronic toxoplasmosis on some human personality factors. Folia Parasitol. 1994; 41: 122-126.

Flegr J, Zitkova, S, Kodym P, Frynta D. Induction of changes in human behavioure by protozoan Toxoplasma gondii. Parasitology. 1996; 113; 49-54.

Flegr J, Kodym P, Tolarova´V. Correlation of duration of latent Toxoplasma gondii infection with personality changes in women. Biol Psychol. 2000; 53: 57– 68.

Flegr, J. Preiss, M. Klose, J. Havlıcek, J. Vitakova, M. Kodym, P. Decreased level ofn psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii Dopamine, a missing link between schizophrenia and toxoplasmosis? Biol Psychol. 2003; 63: 253- 268.

Novotna M, Havlicek J, Smith P, Kolbekova P, Skallova A, Klose J, Gasva Z, Pisacka M, Sechovska M, Flegr J. Toxoplasma and reaction time: role of toxoplasmosis in the origin, preservation and geographical distribution of Rh blood group polymorphism. Parasitology. 2008; 135: 1253–1261.

Lindova J, Novotna M, Havlıcek J, Jozıfkova E, Skallova A, Kolbekova P, Hodny Z, Kodym P, Flegr J. Gender differences in behavioural changes induced by latent toxoplasmosis. Int J Parasitol. 2006; 36: 1485–1492.

Havlicek J, Gasova Z, Smith AP, Zvara K, Flegr J. Decrease of psychomotor performance in subjects with latent `asymptomatic' toxoplasmosis. Parasitology. 2001; 122: 515-520.

Novotná, M. Hanusova, J. Klose, J. Preiss, M. Havlicek, J. Roubalová, K. Flegr, J. Probable neuroimmunological link between Toxoplasma and cytomegalovirus infections and personality changes in the human host. BMC Infect Dis. 2005; 5:54.

Flegr J, Novotná M, Lindová J, Havlíček H. Neurophysiological effect of the Rh factor. Protective role of the RhD molecule against Toxoplasma-induced impairment of reaction times in women. Neuroendocrinol Lett. 2008; 29: 475–481.

Webster JP. The effect of Toxoplasma gondii and other parasites on activity levels in wild and hybrid Rattus norvegicus. Parasitology. 1994; 109:583–589.

Berdoy M, Webster JP, Macdonald DW. Parasite-altered behaviour: is the effect of Toxoplasma gondii on Rattus norvegicus specific? Parasitology. 1995; 111: 403–409.

Hodcova H, Kodym P, Flegr J. Poorer results of mice with latent toxoplasmosis in learning tests: impaired learning processes or the novelty discrimination mechanism? Parasitology. 2007; 134: 1329–1337.

Berdoy M, Webster JP, Macdonald DW. Fatal attraction in rats infected with Toxoplasma gondii. Proc R Soc Lond B. 2000; 267:1591–1594.

Vyas A, Seon-Kyeong K, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioural changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odours. Proc Nat Acad Sci USA. 2007; 104: 6442–6447.

Lamberton PHL, Donnelly CA, Webster JP. Specificity of the Toxoplasma gondii-altered behaviour to definitive versus nondefinitive host predation risk. Parasitology. 2008; 135: 1143–1150.

Freedman R. Schizophrenia. N Engl J Med. 2003; 349: 1738–1749.

Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011; 93: 23–58.

Yolken RH, Bachmann S, Rouslanova I, Lillehoj E, Ford G, Torrey EF, Schroeder J. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001; 32:842–844.

Cetinkaya Z, Yazar S, Gecici O, Namli MN. Anti-Toxoplasma gondii antibodies in patients with schizophrenia—preliminary findings in a Turkish sample. Schizophr Bull. 2007; 33:789–91.

Dogruman-Al F, Aslan S, Yalcin S, Kustimur S, Turk S. A possible relationship between Toxoplasma gondii and schizophrenia: A seroprevalence study. Int J Psychiatry Clin Pract. 2009; 13: 82-87.

Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, Torrey EF, Yolken RH. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 25:4–8.

Alipour A, Shojaee S, Mohebali M, Tehranidoost M, Abdi Masoleh F, Keshavarz H. Toxoplasma infection in schizophrenia patients: A comparative study with control group. Iranian J Parasitol. 2011; 6: 31-37.

Daryani A, Sharif M, Hosseini SH, Karimi SA, Gholami S. Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Trop Biomed. 2010; 27: 476–482.

Hamidinejat H, Ghorbanpoor M, Hosseini H, Alavi SM, Nabavi L, Razi Jalali MH, Pourmehdi Borojeni M, Jafari H, Mohammadaligol S. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis. 2010; 14: e978–e981.

Yuksel P, Alpay N, Babur C, Bayar R, Saribas S, Karakose AR, Aksoy C, Aslan M, Mehmetali S, Kilic S, Balcioglu I, Hamanca O, Dirican A, Kucukbasmaci A, Oner A, Torun MM, Kocazeybek B. The role of latent toxoplasmosis in the aetiopathogenesis of schizophrenia – the risk factor or an indication of a contact with cat? Folia Parasitol. 2010; 57: 121–128.

Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, Riedel M, Müller N. The association of infectious agents and schizophrenia. World J Biol Psychiatry. 2010; 11: 739-743.

Wang HL, Wang GH, Li QY, Shu S, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatrica Scand. 2006; 114: 40–48.

Wang H, Yolken RH, Hoekstra PJ, Burger H, Klein HC. Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: The TRAILS study. Schizophr Res. 2011; 129: 47-51.

Alvarado-Esquivel C, Alanis-Quiñones OP, Arreola-Valenzuela MA, Rodríguez- Briones A, Piedra- Nevarez LJ, Duran-Morales E, Estrada-Martínez S, Martínez- García SA, Liesenfeld O. Seroepidemiology of Toxoplasma gondii infection in psychiatric inpatients in a northern Mexican city. BMC Infect Dis. 2006; 6:178.

Alvarado-Esquivel C, Urbina-Álvarez JD, Estrada-Martínez S, Torres-Castorena A, Molotla-de-León G, Liesenfeld O, Dubey JP. Toxoplasma gondii infection and schizophrenia: A case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int. 2011; 60: 151–155.

El-Sahn AA, Shatat HZ, Ghitany EM. Seropositivity of toxoplasmosis in patients with schizophrenia. J Egypt Public Health Assoc. 2005; 80: 509-24.

Tanyuksel M, Uzun O, Araz E, Koru O, Babur C. Possible role of toxoplasmosis in patients with first-episode schizophrenia. Turk J Med Sci. 2010; 40: 399-404.

Bachmann S, Schröder J, Bottmer C, Torrey EF, Yolken RH. Psychopathology in first-episode schizophrenia and antibodies to Toxoplasma gondii. Psychopathology. 2005; 38:87-90.

Amminger GP, McGorry PD, Berger GE, Wade D, Yung AR, Phillips LJ, Harrigan SM, Francey SM, Yolken RH. Antibodies to infectious agents in individuals at ultra high risk for psychosis. Biol Psychiatry. 2007; 61:1215-7.

Hinze-Selch D, Däubener W, Eggert L, Erdag S, Stoltenberg R, Wilms S. A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull. 2007; 33:782-8.

Torrey EF, Bartko JJ, Lun Z-R & Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2007; 33: 729–736.

Niebuhr DW, Millikan AM, CowanDN, Yolken R, Li Y &Weber NS. Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am J Psychiatry. 2008; 165: 99–106.

Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality. Schizophr Bull. 2007; 33: 737–740.

Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, Sørensen TL, Hougaard D, Torrey EF, Yolken R. Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth. Biol Psychiatry. 2007; 61:688–693.

Brown AS, Schaefer CA, Quesenberry CP, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia, in adult offspring. Am J Psychiatry. 2005; 162:767–773.

Horacek J, Flegr J, Tintera J, Verebova K, Spaniel F, Novak T, Brunovsky M, Bubenikova-Valesova V, Holub D, Palenicek T, Höschl C. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: Voxel-basedmorphometry (VBM) study. World J Bioll Psychiatry.2011;(doi:10.3109/15622975.20 11.573809). [Epub ahead of print].

Xiao J, Buka SL, Cannon TD, Suzuki Y, Viscidi RP, Torrey EF, Yolken RH. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microb Infect. 2009; 11: 1011_1018.

Groër MW, Yolken RH, Xiao JC, Beckstead JW, Fuchs D, Mohapatra SS, Seyfang A, Postolache TT. Prenatal depression and anxiety in Toxoplasma gondii-positive women. Am J Obstet Gynecol. 2011; 204(5):433.e1-7.

Pedersen MG, Stevens H, Pedersen CB, Nørgaard-Pedersen B, Mortensen PB. Toxoplasma infection and later development of schizophrenia in mothers. Am J Psychiatry. 2011; 168(8):814-21.

Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003; 62: 237-244.

Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. Evaluation of the moodstabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J Parasitol. 2008; 94: 555-557.

Goodwin DG, Strobl JS, Lindsay DS. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J Parasitol. 2011; 97:148-51.

Kar N, Misra B. Toxoplasma seropositivity and depression: a case report. BMC Psychiatry. 2004; 4:1.

National Institute of Mental Health. Obsessive- compulsive disorder, OCD; 2011. Available from: http://www.nimh.nih.gov/health/topics/obs essive-compulsive-disorder-cd/index.shtml.

Miman O, Kusbeci OY, Aktepe OC, Cetinkaya Z. The probable relation between Toxoplasma gondii and Parkinson’s disease. Neuroscience Lett. 2010; 475: 129–131.

Brynska A, Tomaszewicz-Libudzic E, Wolanczyk T. Obsessive-compulsive disordermand acquired toxoplasmosis in two children. Eur Child Adolesc Psychiatry. 2001; 10: 200–204.

WHO. World report on violence and health. Geneva: World Health Organization; 2002.

Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, Balis T, Cabassa JA, Scrandis DA, Tonelli LH, Postolache TT. Toxoplasma gondii antibody titers and history of suicide at tempts in patients with recurrent mood disorders. J Nerv Mental Dis. 2009; 197: 905-908.

Yagmur F, Yazar S, Ozcan Temel H, Cavusoglu M. May Toxoplasma gondii increase suicide attempt-preliminary results in Turkish subjects? Forens Sci Int. 2010; 199: 15-17.

Ling VJ, Lester D, Mortensen PB, Langenberg PW, Postolache TT. Toxoplasma gondii seropositivity and suicide rates in women. J Nerv Ment Dis. 2011; 199(7):440-4.

WHO. Global status report on road safety. Geneva: World Health Organization; 2009.

Flegr J, Havlícek J, Kodym P, Malý M, Smahel Z. Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study. BMC Infect Dis. 2002; 2:11.

Yereli K, Balciog˘lu IC, O¨ zbilgin A. Is Toxoplasma gondii a potential risk for traffic accidents in Turkey? Forens Sci Int. 2006; 163: 34–37.

Kocazeybek b, Ali Oner Y, Turksoy R, Babur C, Cakan H, Sahip N, Unal A, Ozaslan A, Kılıc S, Saribas S, Aslan M, Taylan A, Koc S, Dirican A, Bulent Uner H, Oz V, Ertekin C, Kucukbasmaci o, Mamal Torun M. Higher prevalence of toxoplasmosis in victims of traffic accidents suggest increased risk of traffic accident in Toxoplasma- infected inhabitants of Istanbul and its suburbs. Forens Sci Int. 2009; 187: 103–108.

Flegr J, Klose J, Novotná M, Berenreitterová M, Havlíček J. Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study. BMC Infect Dis. 2009; 9:72.

Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003; 348: 1356-1364.

Yilmaz KO, Ozlem m, Mehmet Y, Orhan Cem A, Suleyman Y. Could Toxoplasma gondii have any role in Alzheimer disease? Alzheimer Dis Assoc Disorder. 2011; 25: 1–3.

Miman O, Kusbeci OY, Aktepe OC, Cetinkaya Z. The probable relation between Toxoplasma gondii and Parkinson’s disease. Neuroscience Lett. 2010; 475: 129–131.

Celik T, Kamisli O, Babür C, Cevik MO,Oztuna D, Altinayar S. Is there a relationshi between Toxoplasma gondii infection and idiopathic Parkinson's disease? Scand J Infect Dis. 2010; 42: 604-8.

Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003; 16: 165–70.

Preux PM, Druet-Cabanac M. Epidemiology and etiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 2005; 4: 21–31.

Stommel EW, Seguin R, Thadani VM, Schwartzman JD, Gilbert K, Ryan KA, Tosteson TD, Kasper LH. Cryptogenic epilepsy: An infectious etiology? Epilepsia. 2001; 42:436–438.

Yazar S, Arman, F, Yalcin S, Demirtas F, Yaman O, Sahin I. Investigation of probable relationship between Toxoplasma gondii and cryptogenic epilepsy. Seizure. 2003; 12: 107–109.

Akyol A, Bicerol B, Ertug S, Ertabaklar H. Epilepsy and seropositivity rates of Toxocara canis and Toxoplasma gondii. Seizure. 2007; 16: 233—237.

Koseoglu E, Yazar S, Koc I. Is Toxoplasma gondii a causal agent in migraine? Am J Med Sci. 2009; 338: 120-122.

Palmer BS. Meta-analysis of three case controlled studies and an ecological study into the link between cryptogenic epilepsy and chronic toxoplasmosis infection. Seizure. 2007; 16: 657-663.

Vasconcelos MM. Mental retardation. J Pediatr (Rio J). 2004; 80(2): S71-82.

Stern H, Booth JC, Elek SD, Fleck DG. Microbial causes of mental retardation the role of prenatal infections with cytomegalovirus, rubella virus, and Toxoplasma. Lancet. 1969; 294: 443-448.

Alford CA, Stagno S, Reynolds DW. Congenital toxoplasmosis: clinical, laboratory and therapeutic considerations, with special reference to subclincial disease. Bull NY Acad Med. 1974; 50 160–181.

Caiaffa WT, Chiari CA, Figueiredo RP, Orefice F, Antunes CM. Toxoplasmosis and mental retardation-report of a case-control study. Mem Inst Oswaldo Cruze. 1993; 88: 253-261.

Kaňková Š, Kodym P, Frynta D, Vavrinova R, Kubena A, Flegr J. Influence of latent toxoplasmosis on the secondary sex ratio in mice. Parasitology. 2007; 134: 1709–1717.

Kaňková Š, Šulc J, Nouzová K, Fajfrlík K, Frynta D, Flegr J. Women infected with parasite Toxoplasma have more sons. Naturwissenschaften. 2007; 94:122–127.

Kaňková Š, Holáň V, Zajícová A, Kodym P, Flegr J. Modulation of immunity in mice with latent toxoplasmosis—the experimental support for the immunosuppression hypothesis of Toxoplasma-induced changes in reproduction of mice and humans. Parasitol Res. 2010; 107:1421–1427.

Xiao J, Jones-Brando L, Talbot CC, Yolken RH. Differential effects of three canonical Toxoplasma strains on gene expression in human neuroepithelial cells. Infect Immun. 2011; 79: 1363–1373.

Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K, Mayr T, Kirisits MJ, Wollmann R, Ferguson DJ, Roberts CW, Hwang JH, Trendler T, Kennan RP, Suzuki Y, Reardon C, Hickey WF, Chen L, McLeod R. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation. 2008; 5:48.

Stibbs HH. Changes in brain concentration of catecholamines and indoleamines in Toxoplasma gondii infected mice. Annal Trop Med Parasitol. 1985; 79: 153- 157.

Laakso MP, Soininen H, Partanen K, Helkala EL, Hartikainen P, Vainio P, Hallikainen M, Hänninen T, Riekkinen PJ. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions. J Neural Transmission. 1995; 9: 73-86.

Horna R, Ostertunb B, Frica M, Solymosib L, Steudelb A, Möllera HJ. Atrophy of hippocampus in patients with Alzheimer's disease and other diseases with memory impairment. Dementia. 1996; 7:182-186.

Shenton ME, Gerig G, McCarley RW, Székely G, Kikinis R. Amygdala-hippocampal shape differences in schizophrenia: the application of 3D shape models to volumetric MR data. Psychiatry Res. 2002; 115(1-2):15-35.

Bogerts B, Lieberman JA, Ashtari M, Bilder RM, Degreef G, Lerner G, Johns C, Masiar S. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry. 1993; 33: 236-246

Mervaala E, Föhr J, Könönen M, Valkonen- Korhonen M, Vainio P, Partanen K, Partanen J, Tiihonen J, Viinamäki H, Karjalainen AK, Lehtonen J. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med. 2000; 30:117-25.

Tanskanen P, Veijola HM, Piippo UK,Haapea M, Miettunen JA, Pyhtinen J, Bullmore ET, Jones PB, Isohanni MK. Hippocampus and amygdala volumes in schizophrenia and other psychoses in the Northern Finland 1966 birth cohort. Schizophr Res. 2005; 75: 283– 294.

Tebartz van Elst L, Baeumer D, Lemieux L, Woermann FG, Koepp M, Krishnamoorthy S, Thompson PJ, Ebert D, Trimble MR. Amygdala pathology in psychosis of epilepsy A magnetic resonance imaging study in patients with temporal lobe epilepsy. Brain. 2001; 25: 140-149.

Taupin P. The hippocampus neurotransmission and plasticity in the nervous system. Nova Science Publishers; 2007.

Baxter MG, Murray EA. The amygdala and reward. Nat Rev Neuroscience. 2002; 3: 563-573.

Davis KL, Kahn KS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991; 148: 1474-1486.

Wolfe N, Katz ID, Albert ML, Almozlino A, Durso R, Smith MC, Volicer L. Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major de pression, and Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990; 53: 915–917.

Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression . J Comarat Nuerol. 1989; 287: 373-392.

Skallova A, Kodym P, Frynta D, Flegr J. The role of dopamine in Toxoplasma induce behavioural alterations in mice: an ethological and ethopharmacological study. Parasitology. 2006; 133: 525–535.

Webster JP, Lamberton PHL, Donnelly CA, Torrey EF. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and antiparasite medication on Toxoplasma gondii’s ability to alter host behaviour. Proc R Soc B. 2006; 273: 1023–1030.

Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS ONE. 2009; 4(3): e4801 doi:10.1371/journal.pone.0004801.

Müller M. Immunological and infectious aspects of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254: 1–3.

Müller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev. 2010; 6: 213–220.

Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to Toxoplasma gondii. Int J Parasitol. 2009; 39: 23–39.

Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004; 161: 889–895

Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun. 2001; 15: 411–420.

Rostami Nejad M, Jahani Sherafat S, Roshani M, Telkabadi M, Lahmi F, Cheraghipour K, Kaboli AR, Alavi-Moghaddam M. The evaluation of interleukin-8 chemokine in chronic and acute Toxoplasma gondii infection. Gastroenterol Hepatol Bed Bench. 2011; 4(1): 34-37.

Jue CH, Chockalingam A, Leifer CA. Early response of mucosal epithelial cells during Toxoplasma gondii infection. J Immunol. 2009; 183:7420-7.

Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22: 947–957.

Maes M, Bosmans E, Calabrese J, Smith R,Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J Psychiatric Res. 1995; 29: 141-152.

Ganguli R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV, Rabin BS. Serum Interleukin- 6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994; 51:1-10.

Lin A, Kenis G, Bignotti S, Tura GJB, De Jong R, Bosmans E, Pioli R,Altamura C, Scharpé S, Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum Interleukin- 6. Schizophrenia Res. 1998; 32: 9-15.

Zhang XY, Zhou DF, Zhang PY, Wu GY,Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res. 2002; 57:247-58.

Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry. 2000; 5:150-158.

Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004; 65:940-7.

Jebbari H, Roberts CW, Ferguson DJ, Bluethmann H, Alexander J. A protective role for IL-6 during early infection with Toxoplasma gondii. Parasite Immunol. 1998; 20:231-9.

Lahmar I, Abou-Bacar A, Abdelrahman T, Guinard M, Babba H, Ben Yahia S, Kairallah M, Speeg-Schatz C, Bourcier T, Sauer A, Villard O, Pfaff AW, Mousli M, Garweg JG, Candolfi E. Cytokine profiles in toxoplasmic and viral uveitis. J Infect Dis. 2009; 199:1239-49.

Fischer HG, Nitzgen B, Reichmann G, Hadding U. Cytokine responses induced by Toxoplasma gondii in astrocytes and microglial cells. Eur J Immunol. 1997; 27:1539-48.

Müller N, Riedel M, Ackenheil M, Schwarz MJ. Cellular and humoral immune system in schizophrenia: A conceptual reevaluation. World J Biol Psychiatry. 2000; 1: 173 – 179.

Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neurosci. 1991; 40: 445-452.

Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Res. 2006; 10: 131-148.

Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: A novel target for cognitive enhancement in schizophrenia. Schizophr Bull. 2010; 36: 211–218.

Schwarcz R, Hunter CA. Toxoplasma gondii and schizophrenia: Linkage through astrocyte-derived kynurenic acid? Schizophr Bull. 2007; 33: 652–653.

Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindström LH, Nordin C, Karanti A, Persson P, Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005; 80:315–322.

Erhardt S, Blennow K, Nordin C, Skogh E, Lindstro¨m LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001; 313:96–98.

Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001; 50:521–530.

Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to Toxoplasma gondii. Int J Parasitol. 2009; 39: 23–39.

Däubener W, Spors B, Hucke C, Adam R, Stins M, Kim KS, Schroten H. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect Immun. 2001; 69:6527-31.

Wilson EH, Hunter CA. The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. Int J Parasitol. 2004; 34:543-8.

How to Cite
1.
Dalimi A, Abdoli A. Latent Toxoplasmosis and Human. IJPA. 7(1):1-7.
Section
Articles